Kelyniam Global, Inc. (KLYG) Stock Message Board

Moderator:

Search This Board:

Last Post: 7/22/2021 2:04:25 PM - Followers: 50 - Board type: Free - Posts Today: 0

Canton, Connecticut 06019

www.kelyniam.com

1-800-280-8192

_{The company has no Preferred Stock or Options that convert into Common Stock}

Company Overview

Kelyniam is a Medical Device Manufacturing company that specializes in the production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced polymers. The company's Engineering division is constantly working with medical professionals by allowing them to operate more effectively, improving patient care, and reducing health care cost by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit Kelyniam's website at www.kelyniam.com for more information.

Transfer Agent
Transfer Online
512 SE Salmon Street
Portland, OR 97214

Auditor/Accountant
Malone & Bailey, PC
2925 Briarpark Drive
Suite 930
Houston, Texas 77042

Legal Counsel
Karlen & Stolzar
One North Broadway
Suite 509
White Plains, New York 10601

Corporate Governance

Tennyson Anthony, CEO/Director
Chris Breault, Operations/Director

Finanical News
2014 Year End Financials May 15, 2015

Statement of Income for the Quarter and Twelve Months Ended December 31, 2014 May 15, 2015

2014 Year End Income Statement Comparison May 15, 2015

Balance Sheet Q2 & Q3, 2014 December, 16 2014

Statement of Income for the 2nd and 3rd Quarter Ended September 30, 2014 December, 16 2014

Balance Sheet March 31, 2014 June, 03 2014

Statement of Income for the Quarter and Three Months Ended March 31, 2014 June, 03 2014

2013 Year End Income Statement Comparison April 7, 2014

2013 Year End Financials April 7, 2014

Balance Sheet June 30, 2013 October, 04 2013
==========================================================================================================

Kelyniam Taps New Markets to Fuel Medical Device Growth January 19, 2015

Cranial Implant Company Swears by PEEK, Touts Industry-Leading Turn-Around Time December 19, 2014

Custom Cranial Implant Company Aims For Big Push In 2015 December 11, 2014

Kelyniam Global Acquires MED-ALLY November 19, 2014

Kelyniam Announces Record Net Income and Additions to the Board of Directors June 3, 2014

Kelyniam Global Inc. Revenues Grow 54% from Prior Year April 7, 2014

Kelyniam Global Inc. Unveils New Product April 2, 2014

Kelyniam Global Inc. turns profitable during the second quarter of 2013 September 26, 2013

Kelyniam Global Inc. Announces Continued Revenue Growth & Approval to Sell Overseas May 30, 2013

Kelyniam Custom Cranial Implants Receive Endorsement From Skull Based Neurosurgeon Dr. Ammirati of The Ohio State University Wexner Medical Center January 29, 2013

Updated - Kelyniam Receives 510k approval for Custom Craniofacial Implants September 27, 2012

2014 Year End Income Statement Comparison

KELYNIAM GLOBAL, INC.

	Year End 12/31/2014	Year End 12/31/2013
Sales	$1,788,765	$1,857,516
Cost of Sales	$880,823	$994,672
Gross Profit	$907,942	$862,844
General and administrative expenses	$906,756	$936,744
Income (Loss) from operations	$1,186	($73,900)

Other income (expense)
Interest Income	9	15
Income tax Benefit	-	30,310
Income tax expense	(5,967)	-
Net Loss	(4,772)	(43,575)
Unrealized Gain on investment securities	22,885	15,321
Total comprehensive income (loss)	$18,113	$(28,254)

======================================================================================================

Statement of Income

For the Quarter and Twelve Months Ended December 31, 2014

KELYNIAM GLOBAL, INC.

	Quarter Ending	Year to Date
Sales	$356,213	$1,788,765
Cost of Sales	215,513	880,823
Gross Profit	140,700	907,942
General and administrative expenses	256,530	906,756
(Loss) Income from Operations	(115,830)	1,186
Other Income (expense)
Interest income	1	9
Income taxes	(5,967)	(5,967)
Total other expense	(5,966)	(5,958)
Net Loss	(121,796)	(4,772)
Unrealized gain on investment securities	(27,371)	22,885
Total Comprehensive Income	$(149,167)	$(18,113)

For the 2nd and 3rd Quarter Ended September 30, 2014

KELYNIAM GLOBAL, INC.

June 30, 2014,, September 30, 2014,, Year to Date

Sales $436,865 $455,401 $1,432,552
Cost of Sales 222,138 172,674 665,310
Gross Profit 214,727 282,727 767,242
General and administrative expenses 221,070 210,427 649,445
Income from Operations (6,343) 72,300 117,797
Other Income
Interest income 2 2 8
Net Income (6,341) 72,302 117,805

www.kelyniam.com

STOCKHOLDERS’ EQUITY
Common stock, $.001 par value, 60,000,000 shares authorized,
19,526,800 shares issued, 19,526,800 outstanding 19,017 19,017

Additional paid-in capital 2,436,564 2,436,564

Retained earnings (Deficit) (1,697,763) (1,654,001)

Total stockholders’ equity 757,818 801,580

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $1,444,223 $1,452,852

KELYNIAM GLOBAL, INC.

Internally produced by Kelyniam - these financials have not been reviewed, audited, or compiled.

BALANCE SHEET

June 30, 2014

September 30, 2014

ASSETS
CURRENT ASSETS
Cash $63,599 $75,138
Accounts receivable 212,235 286,855
Inventory 54,576 16,632
Prepaid rent 3,752
Investment securities available for sale 160,777 131,455
Total current assets $491,187 $513,832

CAPITAL ASSETS
Manufacturing Equipment 359,582 359,582
Computer Equipment 24,982 24,982
Furniture and Fixtures 8,043 8,043
Leasehold Improvments 189,455 189,455
582,062 582,062
Less accumulated depreciation (322,483) (335,735)
Total capital assests 259,579 246,327

OTHER ASSETS
License, net of accumulated amortization of $9,930 35,139
License, net of accumulated amortization of $11,458 34,375
Security Deposit 8,000 8,000
Deferred income tax asset 650,318 650,318
Total other assets 693,457 692,693

TOTAL ASSETS $1,444,223 $1,452,852

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Notes payable $78,125 $63,750
Line of Credit - Bank 165,623 165,623
Credit cards payable 987
Commissions payable 47,245 35,150
Accrued expenses 64,293 74,630
Accrued interest 9,803 6,291
Current portion of capital leases 9,282 30,674
Current portion of long-term debt 30,238 26,880
Total current liabilities $405,596 $402,998

LONG-TERM DEBT
Long-term debt, less current portion 229,464 222,809
Capital lease obligations, less current portion 51,345 25,465
Total long-term debt 280,809 248,274

STOCKHOLDERS’ EQUITY
Common stock, $.001 par value, 60,000,000 shares authorized,
19,526,800 shares issued, 19,526,800 outstanding 19,017 19,017
Additional paid-in capital 2,436,564 2,436,564
Retained earnings (Deficit) (1,697,763) (1,654,001)
Total stockholders’ equity 757,818 801,580
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $1,444,223 $1,452,852

KLYG
Current Price
Volume:

Bid	Ask	Day's Range


KLYG Detailed Quote

KLYG News: Kelyniam Global reports Q1 results	05/18/2021 05:27:41 AM
KLYG News: Kelyniam Global reports FY results	04/05/2021 05:38:58 AM

Kelyniam Global, Inc. (KLYG)

_{The company has no Preferred Stock or Options that convert into Common Stock}

2014 Year End Income Statement Comparison

KELYNIAM GLOBAL, INC.

Statement of Income

For the Quarter and Twelve Months Ended December 31, 2014

KELYNIAM GLOBAL, INC.

June 30, 2014,, September 30, 2014,, Year to Date

About

Help

Educational

More